HAVAH Therapeutics
Palo Alto
About HAVAH Therapeutics
Originally founded in Australia in 2006, Palo Alto-based HAVAH Therapeutics Inc. is a clinical-stage pharmaceutical company specialising in the development of novel therapeutics for the prevention of breast cancer. Breast cancer prevention is a critical, unmet global need. HAVAH's lead product candidate, T+Ai, is a proprietary breakthrough breast cancer prevention combination therapy - reducing a woman’s risk of breast cancer whilst improving their sense of wellbeing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $1.3M
- Last round: Series Unknown (May 2024)
- Website: havahtx.com
- Phone: (650)799-4635
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/havah-therapeutics-15623 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.